Equities analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to report sales of $106.76 million for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Genomic Health’s earnings, with estimates ranging from $104.87 million to $108.20 million. Genomic Health posted sales of $92.63 million during the same quarter last year, which suggests a positive year over year growth rate of 15.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, May 1st.
On average, analysts expect that Genomic Health will report full year sales of $445.00 million for the current year, with estimates ranging from $438.47 million to $450.85 million. For the next year, analysts expect that the company will post sales of $492.25 million, with estimates ranging from $480.72 million to $503.40 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Genomic Health.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.02. The business had revenue of $104.56 million for the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a return on equity of 16.86% and a net margin of 6.52%. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share.
In related news, Director Bros. Advisors Lp Baker sold 11,204 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $65.32, for a total transaction of $731,845.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO G Bradley Cole sold 15,000 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $67.61, for a total transaction of $1,014,150.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,871,600 shares of company stock valued at $136,156,302. Insiders own 45.80% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc raised its position in shares of Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after buying an additional 337,664 shares in the last quarter. Vanguard Group Inc. grew its holdings in Genomic Health by 18.6% during the third quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after purchasing an additional 337,664 shares during the period. Norges Bank bought a new stake in Genomic Health during the fourth quarter valued at about $20,975,000. Copper Rock Capital Partners LLC bought a new stake in Genomic Health during the fourth quarter valued at about $18,630,000. Finally, FMR LLC grew its holdings in Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.
NASDAQ:GHDX opened at $65.93 on Wednesday. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 62.79 and a beta of 0.95. Genomic Health has a 52 week low of $31.05 and a 52 week high of $92.18.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Read More: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.